Introduction
Systemic AL (amyloid light chain) amyloidosis (AL-A) is a clonal plasma cell dyscrasia characterized by the synthesis of monoclonal light chains, potentially leading to the formation of beta-pleated sheets, which may be deposited in tissues, leading to progressive multiple organ failure and death ( , ). The most common clinical presentation of AL-A includes renal involvement, characterized by 1 2 nephrotic-range proteinuria, with a progressive worsening of renal function and congestive heart failure ( , ). Cardiac dysfunction is 3 4 considered to be the most important prognostic factor, patients with congestive heart failure having a median survival close to four months ( ). 5
The optimal curative treatment for AL-A remains a matter of debate. Intravenous melphalan treatment followed by autologous stem cell transplantation (SCT) was initially reported to be the most effective treatment for eligible patients (
). However, a recent 6 -8 randomized survey in France showed that high doses of melphalan followed by autologous stem cell rescue was not superior to standard-dose melphalan plus dexamethasone treatment in terms of AL-A outcome ( ). Eligibility criteria for SCT differ between 9 hematologic centers, because this treatment is associated with high levels of mortality, which are increased by cardiac and/or renal involvement ( , ). For this reason, most clinicians exclude this therapeutic approach in patients with severe organ dysfunction, 10 11 particularly in cases of kidney and heart failure. Recent data have suggested that the eligibility criteria for autologous SCT in patients with severe cardiac or renal involvement should be reconsidered. The therapeutic options include sequential heart transplantation and autologous SCT for patients with severe cardiac amyloid infiltration ineligible for exclusive SCT ( ), and kidney transplantation 12 -15 followed by high-dose myeloablative chemotherapy and autologous SCT in patients with severely impaired kidney function considered unsuitable for SCT ( 
17
). Immunological tests were negative, complement levels were in the normal range and no cryoglobulinemia was detected. Bone 18 marrow aspirate showed the marrow to be moderately hypercellular, with normally maturing hematopoietic progenitors. Morphologically normal plasma cells that represent less than 10 of the total cells with no Congo red-stained deposits were observed on bone marrow % examination. Bone X ray showed no osteolytic lesions. The renal biopsy specimen consisted of renal cortex with 16 glomeruli. Light microscopy of paraffin sections showed expansion of the mesangium by amorphous, weakly periodic acid-Schiff positive material.
Congo-red stained deposits were found both along the capillary walls in the mesangial matrix and in the arteriole wall. We detected light Immunosuppression consisted of induction with antithymocyte globulin (thymoglobulin, M rieux) for 5 days, combined with é methylprednisolone during (1000 mg) and after (500 mg at 24 and 48 hours) surgery. Prednisone was initiated after extubation, with an oral dose of 1 mg/kg per day, and was progressively tapered to 0.2 mg/kg per day after two months. Mycophenolate mofetil (MMF) was administered on day 5, at a dose of 2 g per day, which was subsequently adjusted to ensure clinical safety. Tacrolimus treatment was initiated on day 3 and serum Tacrolimus trough concentrations were maintained at 8 to 10 ng/ml. Twenty-eight days after transplantation, the patient presented biopsy-proven acute heart rejection grade 3A without hemodynamic compromise or echocardiographic modification and without concomitant kidney rejection on kidney allograft biopsy. Intravenous methylprednisolone (500 mg) was administered on three consecutive days and endomyocardial biopsy 10 days later showed grade 0 rejection. The patient s subsequent recovery was uneventful ' and renal function at two months was defined by a serum creatinine concentration of 81 mol/l. Repeated searches for free lambda light μ chain in the serum by nephelometric immunoassays showed no recurrence of AL amyloidosis ( ) and repeated heart allograft Figure 1 biopsies revealed an absence of amyloid deposits on the graft. In September 2005, a bone marrow examination carried out due to neutropenia and thrombopenia showed there to be no excess abnormal plasmocytes and no amyloid deposits.
We assessed intramedullary chimerism by real-time quantitative polymerase chain reaction (RQ-PCR), using the TaqMan kit and an ABI 7700 Sequence Detector (Applera). The detection limit of the assay was 0. remission, with a normal serum free lambda light chain concentration (17 mg/L). Moreover, stem cells were successfully mobilized and collected (5.59 10 /kg progenitor cells collected) three months after combined heart and kidney transplantation, for secondary
autologous SCT in case of hematological recurrence.
Discussion
We report here for the first time the successful outcome, at 36 months, of combined heart and kidney transplantation in a patient with AL-A. This favorable outcome included complete hematologic remission, an absence of amyloid deposits in the cardiac and renal grafts and excellent renal and cardiac allograft function.
Selection of the optimal treatment remains a challenge in patients with AL-A, and solid organ transplantation has recently been identified as a therapeutic option. This approach has previously been assessed only in selected patients with AL-A, particularly those with single organ failure. However, most patients have multisystem disease or are too old to be considered suitable transplant candidates.
Moreover, solid organ transplantation should be accompanied by measures to suppress the underlying clone to prevent the recurrence of amyloid deposits in the graft ( ). Under such conditions, only the results of single-organ transplantation have been reported. Many 19 studies have demonstrated the feasibility of isolated heart transplantation for cardiac AL-A ( ). These patients had high levels of 20 -23 perioperative mortality due to multiple organ failure resulting from the preexisting but undiagnosed presence of deposits in other tissues.
Dual heart and liver transplantation has previously been performed in systemic amyloidosis although indication was related to familial amyloidosis and no AL-A ( ). In the United Kingdom, recurrent amyloid deposition (in patients with primitive AL-A) was consistently 22
observed in the graft in the absence of additional treatment (chemotherapy and/or SCT) a median of 11 months after transplantation (range:
5 to 29.5 months) and the median survival for this group of patients was 29 months ( ). Successful treatment by sequential heart 22 transplantation and autologous SCT has been reported, this approach being developed in response to the high frequency of posttransplant disease recurrence and the risk of disease progression ( ). Cases of cardiac amyloidosis treated by heart transplantation followed by 12 -15 exclusive chemotherapy have also been reported, with an acceptable outcome ( , ).
24
Renal transplantation associated with autologous SCT in patients with end-stage renal failure caused by AL-A has also recently been described ( , ). One of these studies reported uneventful survival in all cases and a median graft survival of 7.4 years among the 21 16 25 patients undergoing renal transplantation ( ). In the study by Leung, no clinical, biochemical or histological evidence of recurrence in the 25 graft or bone marrow was detected during a mean follow-up period of 18 / 9 months, but recurrence in the renal graft was detected in one
This is the first case report, to our knowledge, to describe the outcome of combined heart and kidney transplantation for AL-A. Our patient displayed progressive multisystemic amyloidosis with severe renal, gastrointestinal and heart involvement despite a partial hematologic response to two courses of melphalan/dexamethasone chemotherapy with no improvement of organ function. Finally, given the major risk of rapid death due to heart and kidney failure and the high risk of death in the absence of specific treatment, combined heart and kidney transplantation seems to be the only therapeutic option available to such patients. No additional chemotherapy or SCT was carried out in our patient after renal transplantation, due to the lack of evidence of tumor activity in regular free light chain determinations by immunonephelometric assay. Early complete hematologic responses may have occurred in our patient after only two courses of melphalan-prednisone chemotherapy. Retrospectively, these two courses of treatment seem to have been sufficient to maintain prolonged remission and to abolish monoclonal light chain production. Moreover, we can not exclude that high dose of steroids used during induction therapy could have participate in the clearance of plasma cell since steroid treatment are known to induce plasma cells apoptosis.
Nevertheless, given the risk of primary hemopathy recurrence in this patient, careful follow-up will be required to detect any significant increase in free light chain concentration in the blood.
This case illustrates the feasibility of combined heart and kidney transplantation in patients with severe AL-A. Strategies of this type hold promise for the treatment of other patients with cardiac and renal amyloidosis. Extended follow-up, using a multidisciplinary approach, is required to detect recurrence of the underlying disease and for the initiation of complementary therapies, such as chemotherapy and STC.
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